DAVID ZACCARDELLI
CIK 1627642 · President and CEO · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$807.4K
Companies
7
Total Filings
111
Lifetime Open-Market Net
-$45.62M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VOR | Director | — | $20.00 | — | $0 | 1 | 2026-07-09 |
| SABSW | Director | — | $0.01 | — | $0 | 1 | 2026-01-07 |
| Verona Pharma plc (VRNA) Delisted | President and CEO | 3,285,280 | $106.91 | $351.23M | -$35.28M | 43 | 2025-10-08 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | President & CEO | 0 | — | — | -$253.1K | 4 | 2019-11-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Director | 9,300 | — | — | $200.0K | 3 | 2019-06-12 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Acting Chief Executive Officer | — | — | — | $0 | 2 | 2016-12-13 |
| UTHR | EVP & Chief Operating Officer | 1,542 | $523.63 | $807.4K | -$10.29M | 50 | 2016-05-16 |
Recent Filings · Page 5 of 12
111 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-09-28 | Verona Pharma plc (VRNA) Delisted | Grant (A) | +3,600,000 | $0 | EDGAR |
| 2022-08-11 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −600,000 | -$1.05M | EDGAR |
| 2022-08-03 | Verona Pharma plc (VRNA) Delisted | Mixed | −487,768 | -$328.9K | EDGAR |
| 2022-05-05 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −32,904 | -$16.3K | EDGAR |
| 2022-05-03 | Verona Pharma plc (VRNA) Delisted | Tax (F) | −454,864 | -$237.7K | EDGAR |
| 2022-02-03 | Verona Pharma plc (VRNA) Delisted | Mixed | −6,256 | -$11.8K | EDGAR |
| 2021-11-03 | Verona Pharma plc (VRNA) Delisted | Mixed | −506,904 | -$324.5K | EDGAR |
| 2021-08-09 | Verona Pharma plc (VRNA) Delisted | Sell (S) | −17,656 | -$13.3K | EDGAR |
| 2021-08-04 | Verona Pharma plc (VRNA) Delisted | Mixed | −489,248 | -$382.9K | EDGAR |
| 2021-05-05 | Verona Pharma plc (VRNA) Delisted | Mixed | −2,191,688 | -$1.94M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.